Northern Ireland CDMO, privately held. Founded 1969, headquartered in Craigavon. Over £400M ($500M) expansion program completed 2024, including new 28,000 sq ft GMP peptide API facility doubling capacity. MHRA audited. Offers peptide synthesis from research to commercial scale.